



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
August 16, 2023**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the "Oversight Committee Board Packet" section for the corresponding meeting date.

Call to Order – Agenda Item 1

Presiding Officer Dr. Mahendra Patel announced a quorum present and called the meeting to order at 8:32 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Mahendra Patel, M.D., P.A.

David Cummings, M.D.

Donald (Dee) Margo

Ambrosio Hernandez, M.D.

Will Montgomery (joined via videoconference)

Cindy Barberio Payne

Bill Rice, M.D. (joined via videoconference)

Craig Rosenfeld, M.D.

Presiding Officer Dr. Patel noted that Dr. Rice and Mr. Montgomery joined the meeting via videoconference. He explained that this is an option permitted by the Open Meetings Act and they will count towards a quorum so long as the audience can see and hear them.

Adoption of Minutes from the May 19, 2023, Meeting – Agenda Item 3, Tab 1

MOTION:

On a motion by Mr. Margo and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the minutes of the May 19, 2023, Oversight Committee meeting as presented.

Public Comment – Agenda Item 4

Presiding Officer Dr. Patel noted for the record that no member of the public asked to provide comments.

Chief Executive Officer Report – Agenda Item 5, Tab 2

Presiding Officer Dr. Patel recognized Chief Executive Officer Wayne Roberts to present his report. Mr. Roberts informed the Oversight Committee that if they approved the recommended awards, the agency would have approximately \$7 million remaining in the FY2023 budget. He introduced new personnel and informed members that Ms. Tracey Davies’ accepted a job opportunity at a company in California and would be resigning from CPRIT.

There were no questions for Mr. Roberts.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 6, Tab 3

Presiding Officer Dr. Patel recognized Chief Compliance Officer Vince Burgess and Program Manager Stephen Nance to present the Compliance Report and Compliance Certification of Grant Award Process.

Mr. Nance presented the Compliance Report for the past quarter’s activities. There were no questions for Mr. Nance.

Following Mr. Nance’s report, Mr. Burgess presented the Compliance Certification for the proposed academic research and prevention grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

Chief Scientific Officer Report and Grant Recommendations – Agenda Item 7, Tab 4

Presiding Officer Dr. Patel recognized Dr. Le Beau to provide the academic research program update and introduce the Program Integration Committee’s grant award recommendations.

Dr. Le Beau directed Oversight Committee members to Table 1 on page 4 of the “Proposed Grant Awards” Book, which displayed the Program Integration Committee’s (PIC) proposed award recommendations for academic research grant cycle 23.2 and for recruitment grant cycles 23.5 and 23.6. Dr. Le Beau provided an overview of the recommended awards.

The recommendations comprised six slates of 20 recommended awards totaling \$36,044,691 as displayed below.

Rank	ID	RFA	Final Score	Application Title	Candidate/PI	Organization	Budget
1	RR230040	RFTFM	1.0	First-Time, Tenure- Track: Dr. Graham Erwin	Graham Erwin	Baylor College of Medicine	\$2,000,000
2	RR230042	RFTFM	1.0	First-Time Tenure-Track: Dr. Michael Robertson	Michael Robertson	Baylor College of Medicine	\$2,000,000

Rank	ID	RFA	Final Score	Application Title	Candidate/PI	Organization	Budget
3	RR230054	RFTFM	1.1	Nomination of Xiaofeng Qi, Ph.D. for a CPRIT recruitment of a First-Time Tenure- Track Faculty Member Award	Xiaofeng Qi	The University of Texas Southwestern Medical Center	\$2,000,000
4	RP230446	TRECPDTA	1.1	UTEP Postdoctoral Career Transition Program in Cancer Research	Lu, Weiqin	The University of Texas at El Paso	\$850,000
5	RR230072	RFTFM	1.3	Recruitment of First- Time, Tenure-Track Faculty Members - Simon Eschweiler	Simon Eschweiler	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
6	RP230447	TRECMIA	1.4	Fluorescence-Activated Cell Sorting: FACS Aria Fusion	Kang, Min	Texas Tech University Health Sciences Center	\$901,225
7	RR230078	REI	1.5	Recruitment of Established Investigator, Simon Gayther	Simon Gayther	The University of Texas Health Science Center at San Antonio	\$6,000,000
8	RR230050	RFTFM	1.9	Recruitment of First- Time, Tenure-Track Faculty Member - Dr. Zunlong Ke	Zunlong Ke	The University of Texas at Austin	\$2,000,000
9	RR230052	RFTFM	2.0	First-Time, Tenure- Track: Dr. Varun Venkataramani	Varun Venkataramani	Baylor College of Medicine	\$2,000,000
10	RR230053	RFTFM	2.0	Recruitment of First- Time, Tenure-Track Faculty Member - Dr. Chen Cao	Chen Cao	The University of Texas at Dallas	\$1,800,000
11	RR230066	RFTFM	2.0	Recruitment of First- Time, Tenure-Track Faculty Member - Dr. Qian Yin	Qian Yin	The University of Texas at Austin	\$2,000,000
12	RP230449	TRECMIA	2.0	The acquisition of an instrument suite to set up a high-throughput screening core at Texas A&M University	Liu, Wenshe	Texas A&M University	\$995,767
13	RP230445	TRECMIA	2.2	Core Imaging Instrumentation for Cancer Studies in Rodent Models: Acquisition of an IVIS Spectrum/Quantum GX2 optical/microCT Small Animal Imaging System	Becker, Christopher	Baylor University	\$997,701
14	RR230081	RFTFM	2.6	Nomination of Annika Wylie for CPRIT Recruitment of First- Time Tenure-Track Faculty Member	Annika Wylie	Southern Methodist University	\$2,000,000
15	RP230443	TRECPSA	2.9	"Click" Assembled Colloidal Molecules with Tunable Plasmon Bands as Novel Agents for Photothermal Tumor Therapy	Liang, Hongjun	Texas Tech University Health Sciences Center	\$200,000

16	RP230454	TRECPSA	2.9	Role of transcription factor UBTF in pancreatic cancer	Hafeez, Bilal	The University of Texas Rio Grande Valley	\$200,000
17	RP230431	TRECPSA	3.2	Unraveling the Therapeutic Potential of Osr1 Overexpression in Hepatocellular Carcinoma Management	Xie, Linglin	Texas A&M University	\$200,000
18	RP230444	TRECPSA	3.6	A Role for PSMD2, PSMD7, and PSMD9 in Drug Resistance of Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$200,000
19	RP230451	TRECPSA	3.7	The Role of Renal Lipotoxicity in Carcinogenesis	Bobulescu, Ion	Texas Tech University Health Sciences Center	\$200,000
20	RP230426	Texas CONNECT for Cancer Prevention Study Awards	2.8	Baylor Scott and White Health Texas Connect for Cancer Prevention Cohort	Katherine Sanchez	Baylor Research Institute	\$7,499,998

RFTFM- Recruitment of First-Time Tenure Track Faculty
 REI- Recruitment of Established Investigators
 TREC: MIA - TREC: Major Instrument Award
 TREC: PDTA- TREC: Institutional Postdoctoral Training Award
 TREC: PSA - TREC: Pilot Study Award

In response to a question by an Oversight Committee member inquiring about more information on the CONNECT study, Dr. Le Beau answered she would be available to discuss further after the meeting.

Proposed Academic Research RFAs for Fiscal Year 2024 Cycle 2 (FY24.2)

Dr. Le Beau provided an overview of the Proposed 24.2 RFAs for Academic Research: Core Facility Support Awards, High-Impact/High-Risk Research Awards, Multi-Investigator Research Awards, and Clinical Investigator Award.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the academic research awards process.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member reported a conflict of interest with any award academic research recommendation presented.

Academic Research Awards Approval

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the PIC’s recommendations for the Texas CONNECT for Cancer Prevention Study Award, TREC: Institutional Postdoctoral Training Award, TREC: Major Instrumentation Award, TREC: Pilot Study Award, Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Established Investigators.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Hernandez, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT’s CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Academic Research Proposed FY2024 Cycle 2 RFAs Approval

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Cummings, the Oversight Committee members voted unanimously to approve the Academic Research FY2024 Cycle 2 proposed RFAs.

Chief Prevention Officer Report and Grant Recommendations – Agenda Item 8, Tab 5

Presiding Officer Dr. Patel recognized Prevention Program Manager Carlton Allen to provide the prevention program update and introduce the Program Integration Committee’s grant award recommendations.

Mr. Allen directed Oversight Committee members to the proposed award recommendations for prevention grant cycle 23.2 in the “Proposed Grant Awards” Book at page 38. He provided an overview of the recommended awards.

The recommendations comprised four slates of nine recommended awards totaling \$13,343,163 as displayed below.

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP230078	DI	Implementation and Dissemination of an Evidence-Based Intervention to Increase Tobacco Treatment Capacity in Opioid Treatment Programs	Reitzel, Lorraine R	The University of Texas M. D. Anderson Cancer Center	2.0	1	\$449,776
PP230060	CCC	Coordinating Center for Colorectal Cancer	Shokar, Navkiran K	The University of Texas at Austin	2.3	2	\$3,000,000

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
		Screening Across Texas (CONNECT)					
PP230074	PPC	Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation	Basen-Engquist, Karen M	The University of Texas M. D. Anderson Cancer Center	2.5	3	\$1,999,989
PP230061	PPC	Expansion of HPV Vaccination Among Survivors of Childhood Cancer	Grimes, Allison	The University of Texas Health Science Center at San Antonio	3.2	4	\$999,999
PP230059	CSD	De Casa en Casa 4: Cervical Cancer Screening in Underserved Rural and Border Communities Throughout West and South Texas	Molokwu, Jennifer C	Texas Tech University Health Sciences Center at El Paso	3.3	5	\$2,499,437
PP230003	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Centers Serving Texans who Identify as LGBTQ+	Reitzel, Lorraine R	University of Houston	3.3	6	\$448,835
PP230056	PPC	Continuation and Expansion of a Highly Successful Postpartum HPV Vaccination Program	Berenson, Abbey B	The University of Texas Medical Branch at Galveston	3.6	7	\$2,499,207
PP230030	CSD	ACTION for Big Country	Byrd, Theresa L	Texas Tech University Health Sciences Center	3.7	8	\$997,266
PP230069	DI	Dissemination of the Active Living After Cancer Program	Basen-Engquist, Karen M	The University of Texas M. D. Anderson Cancer Center	3.8	9	\$448,654

CCC: Texas Colorectal Cancer Screening Coordinating Center

CSD: Cancer Screening and Early Detection

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

PPC: Primary Prevention of Cancer

In response to a question by an Oversight Committee member inquiring if grantees screen individuals for multiple cancers, Mr. Allen explained that prevention grantees will often screen individuals for multiple cancer sites if individuals meet the recommended guidelines and if grantees have those services.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member reported a conflict of interest with any of the proposed prevention awards.

Approval Process – Prevention Awards

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rosenfeld, the Oversight Committee members voted unanimously to approve the PIC's nine recommendations for the following mechanisms: Cancer Screening and Early Detection, Colorectal Cancer Coordinating Center, Dissemination of CPRIT-Funded Cancer Control Interventions, and Primary Prevention of Cancer.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rosenfeld, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Chief Product Development Officer Report – Agenda Item 9, Tab 6

Presiding Officer Dr. Patel invited Chief Product Development Officer Dr. Ken Smith, and Senior Program Manager Dr. Abria Magee to provide the product development program update.

As part of the program update, Dr. Magee introduced the newly developed CPRIT Resource Guide, which CPRIT will officially release at the October 2-3 CPRIT Innovations in Cancer Research conference.

An Oversight Committee member complimented the usefulness of the resource guide and recommended that CPRIT consider including economic development offices as well. In response to another Oversight Committee member's question, Dr. Magee confirmed that the guide will be available online via QR code.

An Oversight Committee member asked Dr. Magee about the timeline between submitting a preliminary application and when they receive an invitation to submit a full application. She explained that it generally takes 3-4 weeks.

Dr. Smith responded to another Oversight Committee member's question about the decline in dealmaking in Silicon Valley, noting that this may be one reason that CPRIT is seeing an increased interest in the product development program.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11, Tab 8

Presiding Officer Dr. Patel recognized Mr. Roberts to present his 25 appointments to CPRIT’s Scientific Research and Prevention Programs Committees.

MOTION:

On a motion by Mr. Margo and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the CEO’s 25 appointments to CPRIT’s Scientific Research and Prevention Program Committees.

Advisory Committees – Item 12, Tab 9

Presiding Officer Dr. Patel recognized Mr. Roberts to present the Presiding Officer’s new appointments to the advisory committees. Mr. Roberts presented three appointments to the Clinical Trial Advisory Committee and Dr. Reiser’s appointment to the Product Development Advisory Committee.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Cummings, the Oversight Committee voted unanimously to approve the four advisory committee appointments.

Academic Research Advisory Committee Presentations

Presiding Officer Dr. Patel called on Dr. Le Beau to provide the Clinical Trials Advisory Committee Annual Report.

Dr. Le Beau introduced Dr. William Kelly, who presented an overview of his current research.

Following his presentation, an Oversight Committee member inquired whether Dr. Kelly’s trial focused on before-surgery or after surgery treatment. Dr. Kelly confirmed that this study does not involve surgery.

Another Oversight Committee member asked about dose reduction of the drug, given the side effects. Dr. Kelly explained the options available for investigators.

An Oversight Committee member praised Dr. Kelly for incorporating academic centers and community centers working together.

In response to an Oversight Committee member’s question about quality of life, Dr. Kelly explained that quality of life is something they would like to study in future research. In a follow up question, Dr. Kelly and an Oversight Committee member discussed side effects and how the study is addressing those issues.

Dr. Kelly and an Oversight Committee member discussed the study observations regarding the blood-brain barrier in the context of plans to increase the systemic drug and transportation into

the target site.

At the conclusion of the Oversight Committee's discussion with Dr. Kelly, Dr. Le Beau introduced Dr. David Gerber, who presented updates on the Clinical Trial Network Award and Clinical Trial Participation Awards.

An Oversight Committee member asked about the paperwork challenges. Dr. Gerber explained the assistance provided for people not well versed in completing the paperwork and clarified that he was speaking about the documentation required to apply for the financial reimbursement program. His project partners with a California foundation to provide reimbursement for patients, the form is a single page and does require proof of income. The program navigator meets with the patient to tell them about the program and assists them with completion of the paperwork.

Responding to an Oversight Committee member's follow up question about the turnaround time from form submission to payment, Dr. Gerber explained that he did not have the information on hand but would get the information to the Oversight Committee following the meeting.

An Oversight Committee member commented that more perspective and involvement from individuals living and practicing in non-urban areas would be beneficial to the advisory committee's work and requested that CPRIT add to the Clinical Trials Advisory Committee.

Another Oversight Committee agreed, and explained that it made sense to go out into these non-urban communities and involve more members to make this a more comprehensive effort. Mr. Roberts requested recommendations from the committee for appropriate additions.

After the Oversight Committee's discussion with Dr. Gerber, Dr. Le Beau introduced Dr. Sarah Williams-Blangero, who provided the Geographic Diversity Advisory Committee Annual Report.

Following her report, an Oversight Committee member expressed his strong support for the TREC funding mechanisms and appreciated Dr. Williams-Blangero and the Geographic Diversity Advisory Committee's goals. He recommended that CPRIT increase the ceiling for these awards.

Presiding Officer Dr. Patel and the Oversight Committee members thanked the advisory committee representatives for the presentations.

FY 2024 Honoraria Policy – Agenda Item 13, Tab 10

Presiding Officer Dr. Patel recognized Mr. Roberts to present the FY 2024 honoraria policy.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the FY 2024 Honoraria Policy.

Health & Safety Code Section 102.1062 Waivers – Agenda Item 14, Tab 11

Presiding Officer Dr. Patel recognized Mr. Roberts to present the Health and Safety Code Section 102.1062 waivers for FY 2024. Mr. Roberts presented the two waivers located behind Tab 11 in the Agenda Packet.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the Health and Safety Code Section 102.1062 waivers for FY 2024.

Amendments to 25 T.A.C. Chapters 701 and 703 – Agenda Item 15, Tab 12

Presiding Officer Dr. Patel recognized assistant general counsel Cameron Eckel to present the proposed administrative rule changes. Ms. Eckel reviewed the final orders and the proposed rule change, located behind Tab 12.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the final orders adopting the rule changes to the Texas Administrative Code Chapters 701 and 703 and to approve the publication of the proposed changes to Chapter 701 in the *Texas Register*.

Chief Operating Officer Report – Agenda Item 16, Tab 13

Presiding Officer Dr. Patel recognized Chief Operating Officer Heidi McConnell to present her report.

Following her report, Ms. McConnell responded to an Oversight Committee member's question inquiring about what the lowest interest rate has been. She explained that she believed the interest rate was approximately 0.3% around 2010.

Ms. McConnell provided an update on the CPRIT Conference, noting that there were 400 conference registrants, 55% of whom were CPRIT grantees. She indicated that CPRIT will send out additional reminders about the conference. She reported that an additional exhibitor has signed up since her last update, bringing the total to seven exhibitors.

In response to a question by an Oversight Committee member inquiring whether CPRIT expected companies or academic institutions to be exhibitors, Ms. McConnell responded that a company that is not a current CPRIT grant recipient and does not intend to apply for a grant award may be a conference sponsor or exhibitor. Because every academic institution in the state is a grant recipient or may apply for a CPRIT grant in the future, CPRIT does not consider them for a sponsor or exhibitor.

In response to a question by an Oversight Committee member inquiring if grantees must attend the conference, Ms. McConnell responded that each CPRIT grant program strongly encourages grantees to attend, but does not mandate attendance.

Contract Approvals – Agenda Item 17, Tab 14

Presiding Officer Dr. Patel recognized Ms. McConnell to present contract approvals.

Ms. McConnell presented the recommendation for a FY2024 contract with The Perryman Group for \$195,000 to perform an economic assessment of the cost of cancer in Texas and for FY2024 contract renewals with Alan Boyds Consultants for \$330,000 to perform business due diligence reviews and Business and Financial Management Solutions (BFS) for \$121,409 to monitor peer review meetings.

In response to a question by an Oversight Committee member asking about the timing of the most recent economic assessment, Ms. McConnell responded that The Perryman Group performed the economic assessment of the cost of cancer in Texas last year.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the contracts with The Perryman Group, Alan Boyds Consultants, and BFS.

Subcommittee Business – Agenda Item 19, Tab 16

Presiding Officer Dr. Patel presented the proposed subcommittee assignments for fiscal years 2024 and 2025 located behind Tab 16.

MOTION:

On a motion by Mr. Margo and seconded by Dr. Cummings, the Oversight Committee voted unanimously to approve the new subcommittee assignments for fiscal years 2024 and 2025.

Election of Board Officers – Agenda Item 22, Tab 17

Presiding Officer Dr. Patel presented the Board Governance Subcommittee recommendations for the slate of officers to serve two-year terms ending in August 2025.

MOTION:

On a motion by the chair and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve Dr. David Cummings as Presiding Officer, Cindy Payne as Vice Presiding Officer, and Dr. Ambrosio Hernandez as Board Secretary to serve the Oversight Committee for fiscal years 2024 and 2025.

Following the vote, Mr. Roberts presented Presiding Officer Dr. Patel a gavel on behalf of the CPRIT staff in recognition of Dr. Patel's service and leadership.

Communication Report – Agenda Item 18, Tab 15

Presiding Officer Dr. Patel recognized Communications Director Mark Loeffler to present his report. Mr. Loeffler updated the committee members on communications activities.

There were no questions for Mr. Loeffler.

Future Meeting Dates and Agenda Items – Agenda Item 25, Tab 18

Presiding Officer Dr. Patel stated that the Oversight Committee would not take up standing items 23 and 24. He directed members to tab 18 of the meeting packet for the proposed dates for the Oversight Committee’s regular quarterly meetings and subcommittee meetings for FY 2024.

The next regular Oversight Committee meeting will occur November 15, 2023.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the proposed meeting dates for the regular meetings of the Oversight Committee and the subcommittees for FY 2024.

Internal Auditor Report – Agenda Item 10, Tab 7

Returning to Agenda Item 10, Presiding Officer Dr. Patel recognized Daniel Graves to present the internal auditor report. Mr. Graves provided a status update on current internal audit activities.

There were no questions for Mr. Graves.

Presiding Officer Dr. Patel announced the committee would go into closed session at 11:17 a.m. pursuant to Texas Government Code 551.076 to receive an update on the Internal Audit Report over Information Technology General Controls and to discuss the FY 2023 DIR Texas Cybersecurity Framework Assessment and the personnel action related to the Chief Executive Officer and the Chief Scientific Officer. He asked for Mr. Roberts, Dr. Le Beau, Ms. Doyle, Ms. Nelson, Ms. McConnell, Mr. Burgess, Mr. Nance, Ms. Eckel, Ms. Cusick, Mr. Emenike and Mr. Graves to join the members in closed session. Due to technology restrictions, Oversight Committee members Dr. Rice and Mr. Montgomery did not attend the closed session.

The Board reconvened in open session at 12:01 p.m.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Dr. Hernandez, the Oversight Committee voted unanimously to set the exempt salary for the Chief Scientific Officer position to the legislatively authorized \$639,300 effective on or after September 1, 2023.

MOTION:


On a motion by Dr. Rosenfeld and seconded by Dr. Hernandez, the Oversight Committee voted unanimously to set the exempt salary for the Chief Executive Officer position to the legislatively authorized \$282,277 effective on or after September 1, 2023.

Adjournment – Agenda Item 22

MOTION:

There being no further business, the Oversight Committee voted unanimously to approve Presiding Chair Dr. Patel’s motion to adjourn, which Dr. Hernandez seconded.

The meeting adjourned at 12:02 p.m.

Signature 

Date 11/15/23



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MR 8/16/23
Cindy Barberis Payne
8/16/2023

August 4, 2023

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 29 grant applications totaling \$49,387,854. The PIC recommendations for 20 academic research and 9 prevention grant awards are attached.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Ms. Ramona Magid, CPRIT's Chief Prevention Officer, have prepared overviews of the recommended academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on August 16, 2023. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Le Beau, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

Chair, CPRIT Scientific Review Council

Rank	ID	Award Mechanism	Final Overall Score	Application Title	Candidate/PI	Organization	Budget
1	RR230040	RFTFM	1.0	First-Time, Tenure-Track: Dr. Graham Erwin	Graham Erwin	Baylor College of Medicine	\$2,000,000
2	RR230042	RFTFM	1.0	First-Time Tenure-Track: Dr. Michael Robertson	Michael Robertson	Baylor College of Medicine	\$2,000,000
3	RR230054	RFTFM	1.1	Nomination of Xiaofeng Qi, Ph.D. for a CPRIT recruitment of a First-Time Tenure-Track Faculty Member Award	Xiaofeng Qi	The University of Texas Southwestern Medical Center	\$2,000,000
4	RP230446	TRECPDTA	1.1	UTEP Postdoctoral Career Transition Program in Cancer Research	Lu, Weiqin	The University of Texas at El Paso	\$850,000
5	RR230072	RFTFM	1.3	Recruitment of First-Time, Tenure-Track Faculty Members - SimonEschweiler	Simon Eschweiler	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
6	RP230447	TRECMIA	1.4	Fluorescence-Activated Cell Sorting: FACS Aria Fusion	Kang, Min	Texas Tech University Health Sciences Center	\$901,225
7	RR230078	REI	1.5	Recruitment of Established Investigator, Simon Gayther	Simon Gayther	The University of Texas Health Science Center at San Antonio	\$6,000,000
8	RR230050	RFTFM	1.9	Recruitment of First-Time, Tenure-Track Faculty Member - Dr. Zunlong Ke	Zunlong Ke	The University of Texas at Austin	\$2,000,000
9	RR230052	RFTFM	2.0	First-Time, Tenure-Track: Dr. Varun Venkataramani	Varun Venkataramani	Baylor College of Medicine	\$2,000,000

10	RR230053	RFTFM	2.0	Recruitment of First-Time, Tenure-Track Faculty Member - Dr. Chen Cao	Chen Cao	The University of Texas at Dallas	\$1,800,000
11	RR230066	RFTFM	2.0	Recruitment of First-Time, Tenure-Track Faculty Member - Dr. Qian Yin	Qian Yin	The University of Texas at Austin	\$2,000,000
12	RP230449	TRECMIA	2.0	The acquisition of an instrument suite to set up a high-throughput screening core at Texas A&M University	Liu, Wenshe	Texas A&M University	\$995,767
13	RP230445	TRECMIA	2.2	Core Imaging Instrumentation for Cancer Studies in Rodent Models: Acquisition of an IVIS Spectrum/Quantum GX2 optical/microCT Small Animal Imaging System	Becker, Christopher	Baylor University	\$997,701
14	RR230081	RFTFM	2.6	Nomination of Annika Wylie for CPRIT Recruitment of First-Time Tenure-Track Faculty Member	Annika Wylie	Southern Methodist University	\$2,000,000
15	RP230443	TRECPSA	2.9	"Click" Assembled Colloidal Molecules with Tunable Plasmon Bands as Novel Agents for Photothermal Tumor Therapy	Liang, Hongjun	Texas Tech University Health Sciences Center	\$200,000
16	RP230454	TRECPSA	2.9	Role of transcription factor UBTF in pancreatic cancer	Hafeez, Bilal	The University of Texas Rio Grande Valley	\$200,000
17	RP230431	TRECPSA	3.2	Unraveling the Therapeutic Potential of Osr1 Overexpression in Hepatocellular Carcinoma Management	Xie, Linglin	Texas A&M University	\$200,000

LUDWIG CANCER RESEARCH

ludwigcancerresearch.org

San Diego

18	RP230444	TRECPSA	3.6	A Role for PSMD2, PSMD7, and PSMD9 in Drug Resistance of Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$200,000
19	RP230451	TRECPSA	3.7	The Role of Renal Lipotoxicity in Carcinogenesis	Bobulescu, Ion	Texas Tech University Health Sciences Center	\$200,000

RFTFM- Recruitment of First-Time Tenure Track Faculty
 REI- Recruitment of Established Investigators
 TREC: MIA - TREC: Major Instrument Award
 TREC:PDTA- TREC: Institutional Postdoctoral Training Award
 TREC:PSA - TREC: Pilot Study Award